Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Elranatamab”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Testing effectiveness (Phase 2)Looking for participantsNCT06974786
What this trial is testing

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly DiagnosedMultiple Myeloma (MM)
SCRI Development Innovations, LLC 100
Post-approval studies (Phase 4)Looking for participantsNCT06057402
What this trial is testing

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Pfizer 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04649359
What this trial is testing

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Who this might be right for
Multiple Myeloma
Pfizer 187
Large-scale testing (Phase 3)Looking for participantsNCT06918002
What this trial is testing

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Intergroupe Francophone du Myelome 824
Early research (Phase 1)Looking for participantsNCT06121843
What this trial is testing

Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 147
Not applicableLooking for participantsNCT06855121
What this trial is testing

The Norwegian Immunotherapy in Multiple Myeloma Study

Who this might be right for
Myeloma MultiplePlasma Cell LeukemiaAL Amyloidosis
St. Olavs Hospital 400
Testing effectiveness (Phase 2)Looking for participantsNCT06645678
What this trial is testing

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
YOUNGIL KOH 75
Not applicableNot Yet RecruitingNCT07320326
What this trial is testing

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

Who this might be right for
TCE-RRMM
Peking University People's Hospital 159
Large-scale testing (Phase 3)Active Not RecruitingNCT05317416
What this trial is testing

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Who this might be right for
Multiple Myeloma
Pfizer 854
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06931704
What this trial is testing

Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

Who this might be right for
Multiple Myeloma
Nantes University Hospital 176
Early research (Phase 1)Study completedNCT03269136
What this trial is testing

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 101
Testing effectiveness (Phase 2)Looking for participantsNCT06483100
What this trial is testing

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Who this might be right for
Multiple Myeloma
Washington University School of Medicine 65
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07637578
What this trial is testing

Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)Multiple Myeloma RefractoryMultiple Myeloma in Relapse+1 more
SCRI Development Innovations, LLC 46
Testing effectiveness (Phase 2)Ended earlyNCT05090566
What this trial is testing

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 46
Testing effectiveness (Phase 2)Looking for participantsNCT06997081
What this trial is testing

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Miami 104
Not applicableActive Not RecruitingNCT06479954
What this trial is testing

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Pfizer 1
Not applicableNot Yet RecruitingNCT07391761
What this trial is testing

A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

Who this might be right for
Refractory Multiple Myeloma (RRMM)
Pfizer 30
Testing effectiveness (Phase 2)Looking for participantsNCT06015542
What this trial is testing

Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

Who this might be right for
Multiple Myeloma
Thomas Lund 20
Not applicableStudy completedNCT05565391
What this trial is testing

Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 508
Early research (Phase 1)Study completedNCT04798586
What this trial is testing

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Pfizer 4
Load More Results